These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35315689)

  • 1. Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance.
    Farrington N; McEntee L; Johnson A; Unsworth J; Darlow C; Jimenez-Valverde A; Hornik C; Greenberg R; Schwartz J; Das S; Hope W
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0218121. PubMed ID: 35315689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.
    Landersdorfer CB; Rees VE; Yadav R; Rogers KE; Kim TH; Bergen PJ; Cheah SE; Boyce JD; Peleg AY; Oliver A; Shin BS; Nation RL; Bulitta JB
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.
    Yadav R; Bergen PJ; Rogers KE; Kirkpatrick CMJ; Wallis SC; Huang Y; Bulitta JB; Paterson DL; Lipman J; Nation RL; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spatiotemporal pharmacodynamics of meropenem- and tobramycin-treated Pseudomonas aeruginosa biofilms.
    Haagensen J; Verotta D; Huang L; Engel J; Spormann AM; Yang K
    J Antimicrob Chemother; 2017 Dec; 72(12):3357-3365. PubMed ID: 28961810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Where should antibiotic gradient diffusion strips be crossed to assess synergy? A comparison of the standard method with a novel method using steady-state antimicrobial concentrations.
    Motos A; Avery LM; DeRonde KJ; Mullane EM; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2019 May; 53(5):698-702. PubMed ID: 30880231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant.
    Drusano GL; Liu W; Fregeau C; Kulawy R; Louie A
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2266-73. PubMed ID: 19289521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.
    Yadav R; Rogers KE; Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia.
    Louie A; Liu W; Fikes S; Brown D; Drusano GL
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2788-92. PubMed ID: 23571540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance.
    Darlow CA; Docobo-Perez F; Farrington N; Johnson A; McEntee L; Unsworth J; Jimenez-Valverde A; Gastine S; Kolamunnage-Dona R; de Costa RMA; Ellis S; Franceschi F; Standing JF; Sharland M; Neely M; Piddock L; Das S; Hope W
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0029321. PubMed ID: 33972238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model.
    Bilal H; Bergen PJ; Kim TH; Chung SE; Peleg AY; Oliver A; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.
    Rees VE; Yadav R; Rogers KE; Bulitta JB; Wirth V; Oliver A; Boyce JD; Peleg AY; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model.
    Drusano GL; Neely MN; Yamada WM; Duncanson B; Brown D; Maynard M; Vicchiarelli M; Louie A
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment with doripenem and tobramycin of ventriculitis due to imipenem- and meropenem-resistant Pseudomonas aeruginosa.
    Gelfand MS; Cleveland KO; Mazumder SA
    J Antimicrob Chemother; 2009 Jun; 63(6):1297-9. PubMed ID: 19369268
    [No Abstract]   [Full Text] [Related]  

  • 14. Antibiotic exposure and its relationship to postantibiotic effect and bactericidal activity: constant versus exponentially decreasing tobramycin concentrations against Pseudomonas aeruginosa.
    Li RC; Zhu ZY; Lee SW; Raymond K; Ling JM; Cheng AF
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1808-11. PubMed ID: 9257767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activities of antibiotic combinations against resistant strains of Pseudomonas aeruginosa in a model of infected THP-1 monocytes.
    Buyck JM; Tulkens PM; Van Bambeke F
    Antimicrob Agents Chemother; 2015 Jan; 59(1):258-68. PubMed ID: 25348528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model.
    Avent ML; McCarthy KL; Sime FB; Naicker S; Heffernan AJ; Wallis SC; Paterson DL; Roberts JA
    Microbiol Spectr; 2022 Jun; 10(3):e0052522. PubMed ID: 35442072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable Pseudomonas aeruginosa isolates at simulated epithelial lining fluid concentrations in a dynamic in vitro infection model.
    Tait JR; Bilal H; Kim TH; Oh A; Peleg AY; Boyce JD; Oliver A; Bergen PJ; Nation RL; Landersdorfer CB
    J Glob Antimicrob Resist; 2021 Sep; 26():55-63. PubMed ID: 34023531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Literature review on the distribution characteristics and antimicrobial resistance of bacterial pathogens in neonatal sepsis.
    Wang J; Zhang H; Yan J; Zhang T
    J Matern Fetal Neonatal Med; 2022 Mar; 35(5):861-870. PubMed ID: 32102584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling.
    Bilal H; Tait JR; Lang Y; Zhou J; Bergen PJ; Peleg AY; Bulitta JB; Oliver A; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0220321. PubMed ID: 35041509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.
    Yadav R; Bulitta JB; Wang J; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.